Alexandria Real Estate Equities cut its dividend by 45%, reflecting persistent macro headwinds and sector-specific challenges ...

It’s been a rough few quarters for a life sciences real estate industry grappling with the twin leviathans of a supply glut and dwindling funding for the work its lab tenants do. So it’s little ...

The rapid rise in interest rates has been a major headache for real estate investment trusts (REITs). Rising interest rates increase financing costs, and REITs have to compete with bonds, which are ...

If you’ve ever wondered whether Alexandria Real Estate Equities is undervalued or ready for a rebound, you’re not alone. Evaluating its true worth has never been more relevant. Despite a slight 0.1% ...

Alexandria Real Estate Equities (ARE) stock was the second-biggest percentage decliner on the S&P 500 this week, after the ...

Alexandria Real Estate Equities (ARE) on Wednesday nearly halved its quarterly cash dividend, sending shares down more than ...

Alexandria reported a "throw in everything but the kitchen sink" quarter on Monday, prompting today's sell-off. Revenue, FFO, occupancy rates, and guidance were all down. That said, Alexandria's ...

When investors buy real estate investment trusts (REITs), they aren't just buying real estate companies; they are also buying the large block of tenants that comprise the leasing portfolio within the ...

Alexandria Real Estate Equities delivered excellent fourth-quarter and full-year 2022 results. Focusing on the biotech/life sciences industry has helped insulate the company from the work-from-home ...

Alexandria Real Estate Equities provides sought-after collaborative spaces for bioscience leaders whose needs are only growing. However, the stock is expensive based on its price-to-cash-flow ratio.